Zobrazeno 1 - 10 of 101 pro vyhledávání: '"de Mello Ra"'
1
Potential role of immunotherapy in advanced non-small-cell lung cancer
Autor: de Mello RA, Veloso AF, Esrom Catarina P, Nadine S, Antoniou G
Publikováno v: OncoTargets and Therapy, Vol Volume 10, Pp 21-30 (2016)
Ramon Andrade de Mello,1–3 Ana Flávia Veloso,4 Paulo Esrom Catarina,4 Sara Nadine,5 Georgios Antoniou6 1Department of Biomedical Sciences and Medicine, University of Algarve, Faro, 2Faculty of Medicine, University of Porto, Porto, Portugal; 3Resea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doajarticles::1ca73d22b083b7f8611d29e7cce850ce
https://www.dovepress.com/potential-role-of-immunotherapy-in-advanced-non-small-cell-lung-cancer-peer-reviewed-article-OTT
Zobrazit plný text záznamu
2
EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer
Autor: Carvalho Ls, Sanjay Popat, de Mello Ra, Pedro Madureira, Mary O'Brien, António Araújo
Publikováno v: Pharmacogenomics. 14(14)
Personalized therapy has significantly developed in lung cancer treatment over recent years. VEGF and EGF play a major role in non-small-cell lung cancer (NSCLC) tumor angiogenesis and aggressiveness. EGFR mutation as well as KRAS and ALK rearrangeme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a66f99571d0b4b0522f4872de1053d0c
https://pubmed.ncbi.nlm.nih.gov/24192124
Zobrazit plný text záznamu
3
Akademický článek
Concurrent breast stroma sarcoma and breast carcinoma: a case report
Autor: Carvalho Teresa, Sousa Gabriela, Marques Mariela, Figueiredo Paulo, de Mello Ramon, Gervásio Helena
Publikováno v: Journal of Medical Case Reports, Vol 4, Iss 1, p 414 (2010)
Abstract Introduction Breast cancer is one of the most important health problems in the world and affects a great number of women over the entire globe. This group of tumors rarely presents as bilateral disease and, when it does happen, normally occu
Externí odkaz: https://doaj.org/article/3f26afa6f6bb4e31b2a97c9340937b68
Zobrazit plný text záznamu
4
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
Autor: Konstantinos Kamposioras, Davide Mauri, Konstantinos Papadimitriou, Alan Anthoney, Nadia Hindi, Branka Petricevic, Mario Dambrosio, Antonis Valachis, Pantelis Kountourakis, Jindrich Kopecky, Cvetka Grašič Kuhar, Lazar Popovic, Nataliya P. Chilingirova, George Zarkavelis, Ramon Andrade de Mello, Natalija Dedić Plavetić, Christos Christopoulos, Bianca Mostert, John R. Goffin, Dimitiros Tzachanis, Haytham Hamed Saraireh, Fei Ma, Ida Pavese, Maria Tolia
Publikováno v: Frontiers in oncology
Digital.CSIC. Repositorio Institucional del CSIC
instname
Frontiers in Oncology
Frontiers in Oncology, 10:575148. Frontiers Media S.A.
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Frontiers in Oncology, Vol 10 (2020)
Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8132faa22d2b7c1d1e5da6a705e76dc0
https://doi.org/10.3389/fonc.2020.575148
Zobrazit plný text záznamu
5
The role of pharmacogenomics in personalising the use of tamoxifen in breast cancer
Autor: Johnston, Simon J., Li-Chia Chen, Kwok-Leung Cheung
Publikováno v: Johnston, S J, Chen, L-C & Cheung, K-L 2013, The role of pharmacogenomics in personalising the use of tamoxifen in breast cancer . in RA de Mello (ed.), Tamoxifen, Concepts and Cancer : New Paradigms ., Chapter IX, Nova Science Publishers, New York, pp. 135-46 .
University of Manchester-PURE
Tamoxifen is a well-established endocrine therapy used in the treatment of hormonereceptor positive breast cancer. In recent years, its role in adjuvant and advanced breast cancer settings has been superseded by aromatase inhibitors. The prodrug tamo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::33328bdf8ace0f2b6925e737dcdf5970
https://www.research.manchester.ac.uk/portal/en/publications/the-role-of-pharmacogenomics-in-personalising-the-use-of-tamoxifen-in-breast-cancer(6113653f-6c62-4b49-b30c-3b08e416c9b2).html
Zobrazit plný text záznamu
6
Akademický článek
Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma.
Autor: Valencia G; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru., Roque K; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Ninth of July University (UNINOVE), Sao Paulo, Brazil., Rioja P; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru., Huamán JA; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru., Colomo V; Oncosalud - AUNA, Lima, Peru., Sánchez J; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru., Calle C; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru., Mantilla R; Universidad Nacional Federico Villarreal, Lima, Peru., Morante Z; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru., Fuentes H; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru.; Ninth of July University (UNINOVE), Sao Paulo, Brazil.; Universidad Nacional Federico Villarreal, Lima, Peru.; Universidad de Piura, Piura, Peru., Vidaurre T; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru., Neciosup S; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru., De Mello RA; Ninth of July University (UNINOVE), Sao Paulo, Brazil., Gómez HL; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru.; Universidad Peruana Cayetano Heredia, Lima, Peru., Fernández-Díaz AB; Hospital General Universitario de Valencia, Valencia, Spain., Berrocal A; Hospital General Universitario de Valencia, Valencia, Spain., Castaneda C; Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru.; Oncosalud - AUNA, Lima, Peru.; Universidad Científica del Sur, Lima, Peru.
Publikováno v: OncoTargets and therapy [Onco Targets Ther] 2024 Nov 02; Vol. 17, pp. 871-886. Date of Electronic Publication: 2024 Nov 02 (Print Publication: 2024).
Zobrazit plný text záznamu
7
Editorial & Opinion
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?
Autor: de Mello RA; Department of Oncology, Oxford Cancer Center, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, OX3 7LE, Oxford, UK.; Department of Oncology, University of Oxford, OX3 7DR, Oxford, UK.; Master in Science Post-Graduate Program in Medical Oncology, University of Buckingham, MK18 1EG, Buckingham, UK.; Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University (UNINOVE), Rua Vergueiro, 235, 12o andar, 015250-000, São Paulo, Brazil., Perez KR; Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University (UNINOVE), Rua Vergueiro, 235, 12o andar, 015250-000, São Paulo, Brazil.; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru., Haris PA; Department of Oncology, Oxford Cancer Center, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, OX3 7LE, Oxford, UK.
Publikováno v: Immunotherapy [Immunotherapy] 2024 Apr 30. Date of Electronic Publication: 2024 Apr 30.
Zobrazit plný text záznamu
8
Akademický článek
Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer.
Autor: de Mello RA; Department of Oncology, Oxford Cancer Center, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, OX3 7LE, Oxford, UK.; Department of Oncology, University of Oxford, OX3 7ER, Oxford, UK.; Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University, 015250-000, São Paulo, Brazil., Perez KR; Post Graduation Program in Medicine, Faculty of Medicine, Nine of July University, 015250-000, São Paulo, Brazil.; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru., Vazquez TP; São Paulo Cancer Institute, University of São Paulo, São Paulo, 01246-000, Brazil.
Publikováno v: Immunotherapy [Immunotherapy] 2024 Mar; Vol. 16 (4), pp. 257-266. Date of Electronic Publication: 2024 Jan 10.
Zobrazit plný text záznamu
9
Akademický článek
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices.
Autor: Roque K; Discipline of Medical Oncology, Post-Graduation Programme in Medicine, Faculty of Medicine, Nine of July University (UNINOVE), São Paulo 04101-000, Brazil.; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Av., 2520, Lima 15023, Peru.; Faculty of Medicine, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.; Faculty of Medicine, Universidad Nacional Mayor de San Marcos, Lima 15081, Peru., Ruiz R; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Av., 2520, Lima 15023, Peru.; Escuela Profesional de Medicina Humana-Filial Ica, Universidad Privada San Juan Bautista, Ica 15067, Peru., Mas L; Department of Medical Oncology, Instituto Nacional de Enfermedades Neoplásicas, Angamos Este Av., 2520, Lima 15023, Peru.; Faculty of Medicine, Universidad Peruana Cayetano Heredia, Lima 15102, Peru.; Department of Medical Oncology, Oncosalud-AUNA, Av. Guardia Civil 571-San Borja, Lima 15036, Peru., Pozza DH; Experimental Biology Unit, Department of Biomedicine, Faculty of Medicine of Porto, University of Porto, 4200-319 Porto, Portugal.; i3S-Institute for Research and Innovation in Health and IBMC, University of Porto, 4200-319 Porto, Portugal., Vancini M; Discipline of Medical Oncology, Post-Graduation Programme in Medicine, Faculty of Medicine, Nine of July University (UNINOVE), São Paulo 04101-000, Brazil., Silva Júnior JA; Discipline of Medical Oncology, Post-Graduation Programme in Medicine, Faculty of Medicine, Nine of July University (UNINOVE), São Paulo 04101-000, Brazil., de Mello RA; Discipline of Medical Oncology, Post-Graduation Programme in Medicine, Faculty of Medicine, Nine of July University (UNINOVE), São Paulo 04101-000, Brazil.; Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.; Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.
Publikováno v: Cancers [Cancers (Basel)] 2023 Sep 13; Vol. 15 (18). Date of Electronic Publication: 2023 Sep 13.
Zobrazit plný text záznamu
10
Akademický článek
Advancements of ALK inhibition of non-small cell lung cancer: a literature review.
Autor: Zia V; Post-graduation Program in Translational Medicine, University Federal of São Paulo, São Paulo, Brazil., Lengyel CG; Department of Head and Neck Surgery, National Institute of Oncology Hungary, Budapest, Hungary., Tajima CC; A BP - Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil., de Mello RA; Post-graduation Program in Translational Medicine, University Federal of São Paulo, São Paulo, Brazil.; Post-Graduation Programme in Medicine, Nine of July University (UNINOVE), São Paulo, Brazil.; Section of Medical Oncology, Brazilian Society of Cancerology (SBCANCER), Salvador, Brazil.; Department of Oncology, University of Oxford, Oxford, UK.; Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Publikováno v: Translational lung cancer research [Transl Lung Cancer Res] 2023 Jul 31; Vol. 12 (7), pp. 1563-1574. Date of Electronic Publication: 2023 Jul 04.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje